Chemical and Chemoenzymatic Synthesis of Peptide and Protein Therapeutics Conjugated with Human N ‐Glycans
ChemMedChem · 2024
DOI: 10.1002/cmdc.202300692 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, 2024. Verfasst von Hirofumi Ochiai und 5 weiteren Autor:innen. Beteiligte Einrichtung: GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan. Hauptthemen laut MEDLINE: Polysaccharides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 215 Literaturangaben. Gefördert von: Sendai Research Centre, GlyTech, Inc..
Abstract (Originalsprache)
Glycosylation is one of the most ubiquitous post‐translational modifications. It affects the structure and function of peptides/proteins and consequently has a significant impact on various biological events. However, the structural complexity and heterogeneity of glycopeptides/proteins caused by the diversity of glycan structures and glycosylation sites complicates the detailed elucidation of glycan function and hampers their clinical applications. To address these challenges, chemical and/or enzyme‐assisted synthesis methods have been developed to realize glycopeptides/proteins with well‐defined glycan morphologies. In particular, N ‐glycans are expected to be useful for improving the solubility, in vivo half‐life and aggregation of bioactive peptides/proteins that have had limited clinical applications so far due to their short duration of action in the blood and unsuitable physicochemical properties. Chemical glycosylation performed in a post‐synthetic procedure can be used to facilitate the development of glycopeptide/protein analogues or mimetics that are superior to the original molecules in terms of physicochemical and pharmacokinetic properties. N ‐glycans are used to modify targets because they are highly biodegradable and biocompatible and have structures that already exist in the human body. On the practical side, from a quality control perspective, close attention should be paid to their structural homogeneity when they are to be applied to pharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GlyTech, Inc., 134 Chudoji Minamimachi KRP #1-2F, Shimogyo-ku, Kyoto, 600-8813, Japan.
- Graduate School of Science, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai, 980-8578, Japan.
ORCID-Profile: Hirofumi Ochiai, Yuji Nishiuchi
Förderung
- Sendai Research Centre, GlyTech, Inc.
Zitieren
APA
Ochiai, H., Elouali, S., Yamamoto, T., Asai, H., Noguchi, M., & Nishiuchi, Y. (2024). Chemical and Chemoenzymatic Synthesis of Peptide and Protein Therapeutics Conjugated with Human N ‐Glycans. ChemMedChem. https://doi.org/10.1002/cmdc.202300692
Vancouver
Ochiai H, Elouali S, Yamamoto T, Asai H, Noguchi M, Nishiuchi Y. Chemical and Chemoenzymatic Synthesis of Peptide and Protein Therapeutics Conjugated with Human N ‐Glycans. ChemMedChem. 2024. doi:10.1002/cmdc.202300692
BibTeX
@article{Ochiai2024,
author = {Ochiai, Hirofumi and Elouali, Sofia and Yamamoto, Takahiro and Asai, Hiroaki and Noguchi, Masato and Nishiuchi, Yuji},
title = {Chemical and Chemoenzymatic Synthesis of Peptide and Protein Therapeutics Conjugated with Human N ‐Glycans},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202300692}
}
EUVIMED